China SXT Pharmaceuticals P/E Ratio

China SXT Pharmaceuticals (SXTC) currently reports a P/E ratio of -0.48. That is below the Consumer Discretionary sector average of 21.97. Use the charts on this page to explore China SXT Pharmaceuticals's P/E ratio history and peer comparisons.

China SXT Pharmaceuticals's P/E ratio of -0.48 is lower than the Consumer Discretionary sector average of 21.97. That is roughly 102.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates China SXT Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -0.48, SXTC can look expensive or cheap only in context — versus its own history, growth rate, and Consumer Discretionary peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.48, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 21.97. From there, open related valuation or income-statement pages for China SXT Pharmaceuticals, and consider following SXTC for alerts when major investors trade the stock.

China SXT Pharmaceuticals is classified in the Consumer Discretionary sector. On P/E ratio, it currently shows -0.48 versus a sector average near 21.97. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing SXTC with unrelated industries.